Citadel Advisors
KNSA icon

Citadel Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Citadel Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$902K Buy
14,100
+1,000
+8% +$51.9K ﹤0.01% 8457
2026
Q1 		$631K Buy
+13,100
New +$580K ﹤0.01% 8730
2025
Q4 		– Sell
-14,100
Closed -$548K – 13441
2025
Q3 		$548K Sell
14,100
-18,100
-56% -$588K ﹤0.01% 8910
2025
Q2 		$891K Buy
32,200
+20,100
+166% +$512K ﹤0.01% 7364
2025
Q1 		$269K Buy
12,100
+6,800
+128% +$140K ﹤0.01% 9835
2024
Q4 		$105K Sell
5,300
-4,400
-45% -$100K ﹤0.01% 11422
2024
Q3 		$242K Buy
9,700
+1,800
+23% +$43.9K ﹤0.01% 9748
2024
Q2 		$147K Sell
7,900
-1,200
-13% -$22.5K ﹤0.01% 10376
2024
Q1 		$180K Sell
9,100
-2,800
-24% -$54.7K ﹤0.01% 10493
2023
Q4 		$209K Sell
11,900
-4,500
-27% -$74K ﹤0.01% 9873
2023
Q3 		$285K Buy
16,400
+1,500
+10% +$25.3K ﹤0.01% 9269
2023
Q2 		$210K Sell
14,900
-130,700
-90% -$1.75M ﹤0.01% 9779
2023
Q1 		$1.57M Sell
145,600
-16,200
-10% -$213K ﹤0.01% 5836
2022
Q4 		$2.42M Buy
161,800
+86,100
+114% +$1.25M ﹤0.01% 5124
2022
Q3 		$972K Buy
75,700
+3,400
+5% +$38.7K ﹤0.01% 7053
2022
Q2 		$701K Buy
72,300
+34,500
+91% +$322K ﹤0.01% 7868
2022
Q1 		$376K Buy
37,800
+27,300
+260% +$289K ﹤0.01% 10067
2021
Q4 		$124K Sell
10,500
-20,200
-66% -$248K ﹤0.01% 12487
2021
Q3 		$350K Buy
30,700
+6,500
+27% +$84.6K ﹤0.01% 10714
2021
Q2 		$337K Buy
24,200
+1,400
+6% +$21.3K ﹤0.01% 10987
2021
Q1 		$422K Sell
22,800
-4,600
-17% -$94.1K ﹤0.01% 10055
2020
Q4 		$484K Sell
27,400
-4,600
-14% -$80.8K ﹤0.01% 8200
2020
Q3 		$490K Buy
32,000
+20,800
+186% +$391K ﹤0.01% 7340
2020
Q2 		$285K Buy
+11,200
New +$234K ﹤0.01% 7988

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Citadel Advisors's KNSA Position: Q2 2026 in Review

Citadel Advisors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 91% in Q2 2026, selling an estimated $22.5M and leaving 41,665 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #5923.

Citadel Advisors first reported a position in KNSA in Q2 2018 and has held it in 33 quarters since. The position peaked at $30.6M in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Citadel Advisors held 41,665 shares of Kiniksa Pharmaceuticals worth $2.66M as of Q2 2026.
  • Citadel Advisors sold 433,085 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $22.5M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5923 holding.
  • Citadel Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
  • Citadel Advisors's Kiniksa Pharmaceuticals position peaked at $30.6M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.